NCT00004556|Completed
The Effects of Dextroamphetamine on Brain Function
Mechanisms of Individual Variation of Dextroamphetamine Effects in Normal Human Subjects
Loading search results
Mechanisms of Individual Variation of Dextroamphetamine Effects in Normal Human Subjects
Sponsor study identifier
Secondary identifiers
observational
108
1 country
1
Study Start
September 30, 1991
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
September 25, 2018
Date type not reportedThis date has not been verified as actual or estimated.
The purpose of this study is to determine the effects of the drug dextroamphetamine on the brain function and mood of healthy volunteers. Monoaminergic drugs are substances that affect the nervous system; these drugs can raise, hamper, or have no effect on brain function when given to healthy individuals. Different responses to a drug may be the result of genetic variations. This study will examine the effects of the monoaminergic drug dextroamphetamine on thought and sensorimotor processes while participants perform a variety of tasks. Participants in this study will undergo a medical history, physical examination, blood tests, and an electrocardiogram (EKG). Women of reproductive potential will undergo a pregnancy test. Participants will be given either dextroamphetamine or placebo (an inactive solution) on two occasions separated by at least 3 to 7 days. Participants will then perform neuropsychological tests that will measure attention, problem solving, memory, and ability to complete simple motor tasks.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 25, 2018
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 30, 1991
Date type not reportedThis date has not been verified as actual or estimated.
February 8, 2000
Actual (reported)February 9, 2000
Actual (reported)September 25, 2018
Date type not reportedThis date has not been verified as actual or estimated.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Baxter DN. The mortality experience of individuals on the Salford Psychiatric Case Register. I. All-cause mortality. Br J Psychiatry. 1996 Jun;168(6):772-9. doi: 10.1192/bjp.168.6.772.
Baxter LR Jr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry. 1989 Mar;46(3):243-50. doi: 10.1001/archpsyc.1989.01810030049007.
Karen F Berman, M.D.
National Institute of Mental Health (NIMH)
108 participants (actual enrollment reported by the registry).
First Submitted
February 8, 2000
First Posted
February 9, 2000
Study Start
September 30, 1991
Date type not reportedThis date has not been verified as actual or estimated.
Effects of Stress Hormones on Emotion and Cognition
Contact the study team to confirm eligibility.
Buchsbaum MS, Wu J, DeLisi LE, Holcomb H, Kessler R, Johnson J, King AC, Hazlett E, Langston K, Post RM. Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness. J Affect Disord. 1986 Mar-Apr;10(2):137-52. doi: 10.1016/0165-0327(86)90036-4.
Study Completion
September 25, 2018
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
September 28, 2018
Record last verified: 2018-09-25
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: